container
Dim
Wellbiotech Chairman Faces Detention Over Stock Manipulation Scheme Similar to Sambu Construction

Stock etc

Wellbiotech Chairman Faces Detention Over Stock Manipulation Scheme Similar to Sambu Construction

The decision on whether to detain Yang Namhee, Chairman of Wellbiotech, who is suspected of orchestrating a stock price manipulation scheme similar to the "Sambu Construction stock price manipulation" case, could be made as early as November 15. According to the legal community, the Seoul Central District Court will hold a pretrial detention hearing for Chairman Yang at 3 p.m. today, presided over by Judge Park Jungho, who is in charge of warrants. The special prosecutor's team led by Min Junggi, which is investigating various allegations surrounding First Lady Kim Keonhee, requested an arrest warrant for Chairman Yang the previous day on charges of violating the Capital Markets Act, aggravated breach of trust under the Act on the Aggravated Punishment of Specific Economic Crimes, and embezzlement in the course of work. Chairman Yang is accused of manipulating the stock price by deceiving investors into believing that Wellbiotech would participate in Ukraine reconstruction projects in

GemVax Reports Cumulative Q3 Sales of 55.4 Billion Won... Operating Loss Narrows

GemVax Reports Cumulative Q3 Sales of 55.4 Billion Won... Operating Loss Narrows

GemVax & KAEL announced on November 14 that its cumulative sales for the third quarter of this year reached 55.4 billion won, representing an increase of approximately 24.65% compared to the same period last year. GemVax also reported an operating loss of 3.7 billion won in the third quarter, a reduction in losses compared to the previous year. The company focused its efforts on cost reduction and profitability improvement. If it achieves a turnaround to operating profit on a separate financial basis, the risk of being designated as an investment caution stock will be resolved. A GemVax official stated, "In the fourth quarter of this year, we will continue our efforts to improve performance and reduce costs to enhance profitability," adding, "We will secure financial stability and resources for new drug development through multifaceted reviews and efforts, including additional fundraising." The official further emphasized, "We will carry out research and development without wavering to

EMRO Posts 64 Billion Won in Cumulative Q3 Sales, Up 12.2% Year-on-Year

EMRO, the leading domestic artificial intelligence (AI)-based supply chain management software company, announced on November 14 that its cumulative sales for the third quarter of this year reached 64 billion won on a consolidated financial statement basis. This marks a 12.2% increase compared to the same period last year, setting a new record high. Over the same period, operating profit and net profit reached 1.43 billion won and 2.21 billion won, respectively. Software license sales and cloud service usage fees increased by 4.4% and 6.6%, respectively, compared to the same period last year. The annual technology fees generated from client companies that have adopted EMRO’s solutions rose by 30.6% year-on-year, reaching 12.19 billion won. Several factors contributed to this growth, including the signing of an operations and maintenance contract for a next-generation procurement system with the largest IT company in Korea, as well as the spread of global supply chain crises stemming fr

Dunamu's Q3 Operating Profit Reaches 235.3 Billion Won, Up 54% from Previous Quarter

Dunamu's Q3 Operating Profit Reaches 235.3 Billion Won, Up 54% from Previous Quarter

Dunamu, the operator of the virtual asset exchange Upbit, announced on November 14 that its consolidated operating revenue (sales) for the third quarter of this year reached 385.9 billion won, up 35% from the previous quarter's 285.7 billion won. Operating profit rose by 54% to 235.3 billion won, compared to 152.8 billion won in the second quarter. Net profit for the period also increased by 145% from the previous quarter's 97.6 billion won, reaching 239 billion won. The main factors behind the improved performance appear to be the expansion of trading volume driven by the recovery of the global digital asset market, as well as increased credibility resulting from regulatory and legislative improvements, such as the passage of the United States' "three digital asset bills" (Genius Act, Clarity Act, and anti-CBDC Act) in the House of Representatives. Founded in 2012, Dunamu has established its growth foundation through a range of innovative services, including Upbit and Securities Plu

Won-Dollar Rate Drops 10.7 Won to Mid-1,450s on Strong Market Stabilization Commitment by FX Authorities (Update)

Won-Dollar Rate Drops 10.7 Won to Mid-1,450s on Strong Market Stabilization Commitment by FX Authorities (Update)

The won-dollar exchange rate, which had been on a strong upward trend for two consecutive days, closed sharply lower due to the foreign exchange authorities’ strong commitment to market stabilization. On November 14, in the Seoul foreign exchange market, the won-dollar exchange rate closed weekly trading at 1,457.0 won as of 3:30 p.m., down 10.7 won from the previous trading day. This marked the first time in four days, since November 10, that the weekly closing price ended lower. The exchange rate opened at 1,471.9 won, up 4.2 won from the previous day, and surged to 1,474.9 won within 10 minutes, continuing the upward momentum that had persisted since November 11. However, around 9 a.m., following a market stabilization message from the foreign exchange authorities, the rate immediately dropped by nearly 19 won, plunging to the mid-1,450 won range. The rate further fell to as low as 1,452.0 won at one point after it became known that the joint fact sheet on the Korea-U.S. customs neg

Kyungdong Pharmaceutical "Q3 Operating Profit Reaches 3.1 Billion KRW, Up 484% Year-on-Year"

Kyungdong Pharmaceutical "Q3 Operating Profit Reaches 3.1 Billion KRW, Up 484% Year-on-Year"

Kyungdong Pharmaceutical has significantly improved its profitability in the third quarter through cost efficiency measures, marking its sixth consecutive quarter of operating profit. On November 14, Kyungdong Pharmaceutical announced that its consolidated sales for the third quarter reached 48.9 billion KRW, and operating profit was 3.1 billion KRW, representing a 484% increase compared to the same period last year. Net profit for the same period also surged, reaching 4.4 billion KRW. The substantial improvement in third-quarter profitability is the result of company-wide cost efficiency and efforts to reduce manufacturing costs. In particular, after introducing a marketing agency system, the company was able to streamline fixed costs such as labor expenses, improving its operating margin to 6.3%. Additionally, efforts to reduce manufacturing costs by improving productivity also contributed to enhanced profitability. The company’s overall business remained stable, supported by sale

SAMG Entertainment Achieves 10.9 Billion Won Cumulative Operating Profit in Q3... "Stable Performance Maintained Through Cost Efficiency"

SAMG Entertainment Achieves 10.9 Billion Won Cumulative Operating Profit in Q3... "Stable Performance Maintained Through Cost Efficiency"

SAMG Entertainment announced on November 14 that it recorded cumulative sales of 92.8 billion won and operating profit of 10.9 billion won for the first three quarters. Despite the seasonal off-peak period, the company maintained a stable performance structure, achieving over 10 billion won in operating profit on an annual cumulative basis. In the third quarter, due to the seasonal off-peak effect, consolidated sales reached 21.7 billion won, with an operating loss of 700 million won. Compared to the same period last year, sales decreased by approximately 13.1%, mainly due to the base effect from last year's movie "Hachuping of Love." However, both the cost of goods sold and selling and administrative expenses decreased, continuing the trend of cost structure improvement. Operating loss shrank by about 86.7% compared to the same period last year. While product sales declined in the third quarter due to seasonality, license sales remained at a similar level to the previous quarter, cont

KOSPI Plunges Nearly 4% on Heavy Net Selling by Foreign and Institutional Investors, Closes at 4,011

KOSPI Plunges Nearly 4% on Heavy Net Selling by Foreign and Institutional Investors, Closes at 4,011

The KOSPI plunged nearly 4% to the 4,011 level as both foreign investors and institutions engaged in net selling. On November 14, the KOSPI closed at 4,011.57, down 159.06 points (3.81%) from the previous trading day. The KOSPI opened at 4,061.91, down 2.61% from the previous session. In the afternoon, intensified net selling by foreign investors widened the index's decline. Ultimately, the KOSPI failed to rebound and ended the session at the 4,011 level. Lim Jeongeun, a researcher at KB Securities, explained, "The sharp drop was due to growing concerns about the artificial intelligence (AI) and semiconductor industries, as expectations for an interest rate cut weakened." She added, "Foreign investors recorded a combined net selling of over 3 trillion won in the spot and futures markets." As of 4:30 p.m., according to integrated investor trading data from KRX and NXT, foreign investors and institutions recorded net sales of 2.8576 trillion won and 1.0044 trillion won, respectively. In

top버튼